Patient-reported & health economic outcomes for low-value medications in patients living with dementia / vorgelegt von: Moritz Paul Platen ; 1. Gutachter: Prof. Dr. rer. pol. Steffen Fleßa, 2. Gutachter: Prof. Dr. med. Wolfgang Hoffmann, MPH ; [Betreuer*in: PD Dr. Bernhard Michalowsky]
Arzneiverordnung, Low-value medication.
Background: This study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months. Methods: This analysis was based on longitudinal data of patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple regression models. Results: Over 24 months, Lvm was highly prevalent and significantly increased the risk of hospitalization, increased health care costs, and reduced patients' HRQoL. Conclusion: More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
[2023] |
|---|---|
| Erschienen: |
Greifswald: 2023 |
| Weitere Ausgaben: |
Erscheint auch als Druck-Ausgabe: Patient-reported & health economic outcomes for low-value medications in patients living with dementia |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Platen, Moritz Paul, 1993- [VerfasserIn] |
|---|---|
| Hochschulschrift: |
Dissertation, Rechts- und Staatswissenschaftliche Fakultät der Universität Greifswald, 2023 |
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Arzneimittel |
| Anmerkungen: |
Literaturverzeichnis: Seite xii-xxv |
|---|
| Umfang: |
1 Online-Ressource (PDF-Datei: 145 Seiten, 15021 Kilobyte) ; Diagramme (teilweise farbig) |
|---|
| Weitere IDs: |
urn:nbn:de:gbv:9-opus-87069 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1857891031 |
|---|
| LEADER | 01000nam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1857891031 | ||
| 003 | DE-627 | ||
| 005 | 20230824144809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230824s2023 gw |||||om 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:gbv:9-opus-87069 |2 urn | |
| 035 | |a (DE-627)1857891031 | ||
| 035 | |a (DE-599)KXP1857891031 | ||
| 035 | |a (OCoLC)1393147442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-DE-MV | ||
| 084 | |a 86.56 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Platen, Moritz Paul |d 1993- |e verfasserin |0 (DE-588)1294764357 |0 (DE-627)1851380418 |4 aut | |
| 245 | 1 | 0 | |a Patient-reported & health economic outcomes for low-value medications in patients living with dementia |c vorgelegt von: Moritz Paul Platen ; 1. Gutachter: Prof. Dr. rer. pol. Steffen Fleßa, 2. Gutachter: Prof. Dr. med. Wolfgang Hoffmann, MPH ; [Betreuer*in: PD Dr. Bernhard Michalowsky] |
| 264 | 1 | |a Greifswald |c [2023] | |
| 300 | |a 1 Online-Ressource (PDF-Datei: 145 Seiten, 15021 Kilobyte) |b Diagramme (teilweise farbig) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Literaturverzeichnis: Seite xii-xxv | ||
| 502 | |b Dissertation |c Rechts- und Staatswissenschaftliche Fakultät der Universität Greifswald |d 2023 | ||
| 520 | |a Arzneiverordnung, Low-value medication | ||
| 520 | |a Background: This study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months. Methods: This analysis was based on longitudinal data of patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple regression models. Results: Over 24 months, Lvm was highly prevalent and significantly increased the risk of hospitalization, increased health care costs, and reduced patients' HRQoL. Conclusion: More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care. | ||
| 655 | 7 | |a Hochschulschrift |0 (DE-588)4113937-9 |0 (DE-627)105825778 |0 (DE-576)209480580 |2 gnd-content | |
| 689 | 0 | 0 | |D s |0 (DE-588)4011404-1 |0 (DE-627)106352938 |0 (DE-576)208893350 |a Demenz |2 gnd |
| 689 | 0 | 1 | |D s |0 (DE-588)4003115-9 |0 (DE-627)106390619 |0 (DE-576)208850325 |a Arzneimittel |2 gnd |
| 689 | 0 | 2 | |D s |0 (DE-588)4120926-6 |0 (DE-627)104400307 |0 (DE-576)209539100 |a Arzneiverordnung |2 gnd |
| 689 | 0 | 3 | |D s |0 (DE-588)4130935-2 |0 (DE-627)104584424 |0 (DE-576)209623233 |a Gesundheitsökonomie |2 gnd |
| 689 | 0 | 4 | |D s |0 (DE-588)4112646-4 |0 (DE-627)105835684 |0 (DE-576)209469684 |a Auswirkung |2 gnd |
| 689 | 0 | |5 (DE-627) | |
| 700 | 1 | |a Fleßa, Steffen |d 1966- |e akademischer betreuerin |0 (DE-588)124238394 |0 (DE-627)085728152 |0 (DE-576)170752127 |4 dgs | |
| 700 | 1 | |a Hoffmann, Wolfgang |d 1963- |e akademischer betreuerin |0 (DE-588)1042352690 |0 (DE-627)768680352 |0 (DE-576)393899543 |4 dgs | |
| 700 | 1 | |a Michalowsky, Bernhard |d 1987- |e akademischer betreuerin |0 (DE-588)1294772163 |0 (DE-627)1851397167 |4 dgs | |
| 710 | 2 | |a Universität Greifswald |e Grad-verleihende Institution |0 (DE-588)1168504872 |0 (DE-627)1032330058 |0 (DE-576)511599633 |4 dgg | |
| 751 | |a Greifswald |0 (DE-588)4021965-3 |0 (DE-627)104745835 |0 (DE-576)208941002 |4 uvp | ||
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Platen, Moritz Paul, 1993 - |t Patient-reported & health economic outcomes for low-value medications in patients living with dementia |d Greifswald, 2023 |h xxv, 121 Seiten |w (DE-627)1851388842 |
| 856 | 4 | 0 | |u https://epub.ub.uni-greifswald.de/frontdoor/index/index/docId/8706 |x Verlag |y Volltext |z kostenfrei |
| 912 | |a GBV_ILN_69 | ||
| 912 | |a ISIL_DE-9 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 936 | b | k | |a 86.56 |j Gesundheitsrecht |j Lebensmittelrecht |0 (DE-627)106416995 |
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |0 (DE-627)106423304 |
| 951 | |a BO | ||
| 980 | |2 69 |1 01 |x 0009 |b 437005530X |y x |z 24-08-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 437644121X |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 15-09-23 | ||
| 981 | |2 69 |1 01 |x 0009 |y Volltext |r https://epub.ub.uni-greifswald.de/frontdoor/index/index/docId/8706 |z LF | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://epub.ub.uni-greifswald.de/frontdoor/index/index/docId/8706 | ||
| 983 | |2 69 |1 00 |x DE-9 |8 00 |a PJ 2880 | ||
| 983 | |2 69 |1 00 |x DE-9 |8 01 |a PN 423 | ||
| 985 | |2 69 |1 01 |x 0009 |a 2023.4411 | ||